Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599708 | 1.00 | GPR119 (0.53) | GPR119NR1H2NR1H3RETPOLB | |
| SCHEMBL25003057 | 0.82 | NR1H2 (0.47) | GPR119NR1H2NR1H3RETPOLB | |
| SCHEMBL25216918 | 0.81 | GPR119 (0.57) | GPR119POLBMEN1KMT2ACKS1B | |
| SCHEMBL30599707 | 0.81 | GPR119 (0.57) | GPR119POLBMEN1KMT2ACKS1B | |
| SCHEMBL652725 | 0.78 | MEN1 (0.52) | GPR119NR1H2NR1H3RETPOLB | |
| SCHEMBL652792 | 0.77 | GRM5 (0.53) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL5128070 | 0.77 | GPR119 (0.49) | GPR119NR1H2NR1H3CKS1BSKP1 | |
| SCHEMBL24120242 | 0.77 | GPR119 (0.56) | GPR119NR1H2NR1H3RETPOLB | |
| SCHEMBL21815329 | 0.77 | NR1H2 (0.54) | GPR119NR1H2NR1H3RETPOLB | |
| SCHEMBL38665884 | 0.77 | GPR119 (0.56) | GPR119NR1H2NR1H3RETPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | GPR119 1014/4885NR1H2 2175/4885NR1H3 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.